Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Maschio, Giuseppe; Alberti, Daniele; Janin, G.; Locatelli, Francesco; Mann, Johannes F.E.; Motolese, M; Ponticelli, Claudio; Ritz, Eberhard; Zucchelli, P

doi:10.1056/nejm199604113341502

Cited by 1,613 publications

(806 citation statements)

References 19 publications

Supporting

Mentioning

749

Contrasting

Unclassified

Order By: Relevance

“…29 Inhibition of the renin-angiotensin system either by treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II antagonists has been shown to decrease structural renal damage. 30 However, prospective clinical trials have revealed that calcium channel blockers are almost as effective as ACE inhibitors for preventing the progression of renal failure. 31 In fact, calcium channel blockers have demonstrated diverse effects on glomerular haemodynamics in spontaneously hypertensive rats.…”

Section: Discussionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…[63][64][65][66][67][68][69][70][71] The protein leakage in diabetic hypertensive patients has been attributed to endothelial dysfunction, which is present in both diabetes and hypertension. 72 Microalbuminuria in type II diabetic, 73 or nondiabetic hypertensive 74 patients has been associated, besides renal failure, with cardiovascular complications.…”

Section: Diabetic Nephropathymentioning

confidence: 99%

Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan

Chrysant

Desai

2005

J Hum Hypertens

View full text Add to dashboard Cite

Poorly controlled hypertension is a major risk for cardiovascular morbidity and mortality, strokes, heart failure and renal failure. Despite these devastating complications, blood pressure control of p140/90 mmHg, which is above the current standard, is very poor worldwide, accounting for 34% of hypertensive patients in the United States, and 6% in other countries. The reasons for this poor control of blood pressure include lack of aggressive treatment by physicians, especially for the systolic blood pressure, drug selection and patient compliance. The blood pressure follows a circadian rhythm and is the highest between 0600 to 1200 h, when most complications occur. Long-acting drugs that extend their action to cover this vulnerable period are preferable, especially those that block the renin-angiotensin-aldosterone system, such as ACE inhibitors and angiotensin receptor blockers, and are the most effective in controlling blood pressure and preventing or reducing its cardiovascular and renal complications. With respect to the angiotensin receptor blockers, telmisartan has been demonstrated by several studies to be the longest acting among its class of drugs and to effectively prevent the early morning rise of blood pressure.

show abstract

“…[1][2][3] The Seventh Report of the Joint National Committee suggests ACEIs be used to treat hypertension among patients with these conditions. 4 Despite these recommendations and clinical data supporting the benefits of ACEIs, patients are often not treated with adequate doses or they are simply not prescribed at all.…”

Section: Introductionmentioning

confidence: 99%

A study of the prevalence of significant increases in serum creatinine following angiotension-converting enzyme inhibitor administration

et al. 2005

View full text Add to dashboard Cite

Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Abstract: Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.

Cited by 1,613 publications

References 19 publications

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan

A study of the prevalence of significant increases in serum creatinine following angiotension-converting enzyme inhibitor administration

Contact Info

Product

Resources

About